BCRX icon

BioCryst Pharmaceuticals
BCRX

Overview Fund Activity

195 hedge funds and large institutions have $1.65B invested in BioCryst Pharmaceuticals in 2021 Q2 according to their latest regulatory filings, with 41 funds opening new positions, 61 increasing their positions, 61 reducing their positions, and 36 closing their positions.

Holders
195
Holders Change
+4
Holders Change %
+2.09%
% of All Funds
3.4%
Holding in Top 10
3
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.05%
New
41
Increased
61
Reduced
61
Closed
36
Calls
$81.8M
Puts
$68.5M
Net Calls
+$13.3M
Net Calls Change
-$610K

Top Buyers

1
Fisher Asset Management
1
Fisher Asset Management
Washington
$31.8M
2
Two Sigma Investments
2
Two Sigma Investments
New York
$29.3M
3
Renaissance Technologies
3
Renaissance Technologies
New York
$16.3M
4
BCPEMI
4
Bain Capital Public Equity Management II
Massachusetts
$24.7M
5
D.E. Shaw & Co
5
D.E. Shaw & Co
New York
$13.8M

Top Sellers

1
SCM
1
Sarissa Capital Management
Connecticut
$67.4M
2
HM
2
HealthCor Management
New York
$51.4M
3
Goldman Sachs
3
Goldman Sachs
New York
$12.8M
4
Adage Capital Partners
4
Adage Capital Partners
Massachusetts
$0
5
State Street
5
State Street
Massachusetts
$98.9M
Name Holding Trade Value Shares
Change 		Shares
Change %
WP
226
WealthShield Partners
North Carolina
– -$10K -1,000 Closed
SPIA
227
Steward Partners Investment Advisory
New York
– -$10.2K -1,000 Closed
WAP
228
Wealthcare Advisory Partners
Pennsylvania
– -$4K -400 Closed
NFG
229
Next Financial Group
Texas
– -$1K -100 Closed
6 7 8 9
10